Fuji Pharma signs license agreement for darbepoetin alfa with CKD of South Korea

January 19, 2016 11:28 AM

fuji-pharma-co-biosimilarnews-logo

Fuji Pharma Co., Ltd. announced that the company has signed a license agreement with Chong Kun Dang Pharmaceutical Corporation.

Under the agreement, Fuji Pharma has the exclusive rights in Japan for the development, manufacture, distribute and sell of Darbepoetin Alfa biosimilar.

Darbepoetin Alfa is an erythropoiesis-stimulating agent (ESA) with long acting effects. It is effective for improving renal anemia of non-dialysis chronic kidney disease and hemodialysis patients which widely used in Japanese market.

Darbepoetin Alfa Biosimilar is Fuji Pharma’s second biosimilar product following Filgrastim BS injection Syringe (F), a recombinant human granulocyte colony-stimulating factor (G-CSF) drug which have been marketed in 2013.

Fuji Pharma started a five-year business plan in the fiscal year that ended in September 2019. Under the theme of “Fuji Pharma Branding.” aiming to establish a unique business model that produces synergies in strategic fields by combining brands, generic drugs and contract manufacturing.

Chong Kun Dang is one of the leading pharmaceutical companies in Korea operating globally based on strong pipelines of biopharmaceuticals and other drugs with outstanding R&D capabilities.

Fuji Pharma is aiming to increase the Brand Strength in acute medical care area, which is one of Fuji Pharma’s strategic fields. As a company mission, Fuji Pharma plans to contribute individuals who have chronic renal failure by providing new treatment options.

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)


Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?

Suggestions?

Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!